Immunotherapy

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that with a median of 13-19 months of follow-up, talquetamab continues to […]

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do you feel has been the […]

Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at the BioInnovation Institute (BII) and seeded by the Novo Nordisk Foundation, […]

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme.   The data were from preclinical models of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  DDW’s Diana Spencer has selected five stand-out news headlines this week, which all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances […]

News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer. My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the gut microbiome, can impact the patient’s response to treatment. […]

Hosted by DDW and supported by BPS BioScience and AcroBiosystems, ‘Cancer immunotherapy – where will the future opportunities be?’ will be free to attend on May 10 at 8AM PST | 11AM EST | 4PM BST | 5PM CET.   Join this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   […]

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with suboptimal response. The research by investigators at Harvard Medical […]

New research indicates that for patients with advanced skin cancer, it may be important to maintain normal vitamin D levels when receiving treatment with immune checkpoint inhibitors. The findings are published in CANCER, a peer-reviewed journal of the American Cancer Society. Vitamin D has many effects on the body, including regulation of the immune system. […]

UK company Plasticell and Singapore-based LambdaGen have entered into a strategic collaboration to exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into the human genome. The UK-Singapore partnership is in part financed by a EUREKA GlobalStars competitive grant. The funding has been awarded to enable the […]